Viruses . Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2

[tetano]

Viruses


. 2021 Sep 26;13(10):1936.
doi: 10.3390/v13101936.
Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2


Yi-Sheng Sun ¹ , Jing-Jing Zhou ^{2 3} , Han-Ping Zhu ¹ , Fang Xu ¹ , Wen-Bin Zhao ^{2 3} , Hang-Jing Lu ¹ , Zhen Wang ¹ , Shu-Qing Chen ² , Ping-Ping Yao ¹ , Jian-Min Jiang ¹ , Zhan Zhou ^{2 3 4}



Affiliations

• PMID: 34696367
• DOI: 10.3390/v13101936

Abstract

The novel coronavirus pneumonia (COVID-19) pandemic is a great threat to human society and now is still spreading. Although several vaccines have been authorized for emergency use, only one recombinant subunit vaccine has been permitted for widespread use. More subunit vaccines for COVID-19 should be developed in the future. The receptor binding domain (RBD), located at the S protein of SARS-CoV-2, contains most of the neutralizing epitopes. However, the immunogenicity of RBD monomers is not strong enough. In this study, we fused the RBD-monomer with a modified Fc fragment of human IgG1 to form an RBD-Fc fusion protein. The recombinant vaccine candidate based on the RBD-Fc protein could induce high levels of IgG and neutralizing antibody in mice, and these could last for at least three months. The secretion of IFN-γ, IL-2 and IL-10 in the RBD-stimulated splenocytes of immunized mice also increased significantly. Our results first showed that the RBD-Fc vaccine could induce both humoral and cellular immune responses and might be an optional strategy to control COVID-19.

Keywords: COVID-19; RBD-Fc; cellular immune response; fusion protein; neutralizing antibody; vaccine.